E. Fuse, T. Kuwabara, A. Sparreboom, E. A. Sausville and W. D. Figg, “Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology,” The Journal of Clinical Pharmacology, Vol. 45, No. 4, 2005, pp. 394-403. http://dx.doi.org/10.1177/0091270005274549
 Z. H. Israili and P. G. DaytonHuman, “Alpha-1-Glycoprotein and Its Interactions with Drugs,” Drug Metabolism Reviews, Vol. 33, No. 2, 2001, pp. 161-235. http://dx.doi.org/10.1081/DMR-100104402
 M. J. Edelman, K. S. Bauer Jr., S. Wu, R. Smith, S. Bisacia and J. Dancey, “Phase I and Pharmacokinetic Study of 7-Hydroxystaurosporine and Carboplatin in Advanced Solid Tumors,” Clinical Cancer Research, Vol. 13, No., 2007, pp. 2667-2674. http://dx.doi.org/10.1158/1078-0432.CCR-06-1832
 K. S. Bauer, R. M. Lush, M. A. Rudek, C. Shih, E. Sausville, W. D. Figg, “A High-Performance Liquid Chromatography Method Using Ultraviolet and Fluorescence Detection for the Quantitation of UCN-01, 7-Hydroxystaurosporine, from Human Plasma and Saliva,” Biomedical Chromatography, Vol. 14, No. 5, 2000, pp. 338-343. http://dx.doi.org/10.1002/1099-0801(200008)14:5<338::AID-BMC993> 3.0.CO;2-6
 E. A. Sausville, S. G. Arbuck, R. Messmann, et al., “Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients with Refractory Neoplasms,” Journal of Clinical Oncology, Vol. 19, 2001, pp. 2319-2333.
 S. Akinaga, K. Gomi, M. Morimoto, T. Tamaoki and M. Okabe, “Antitumor Activity of UCN-01, a Selective Inhibitor of Protein Kinase C, in Murine and Human Tumor Models,” Cancer Research, Vol. 51, No. 18, 1991, pp. 4888-4892.
 R. H. Mathijssen, F. A. de Jong, W. J. Loos, J. M. van der Bol, J. Verweij and A. Sparreboom, “Flat-Fixed Dosing versus Body Surface Area Based Dosing of Anticancer Drugs in Adults: Does it Make a Difference?[See Comment],” Oncologist, Vol. 12, No. 8, 2007, pp. 913-923. http://dx.doi.org/10. 1634/theoncologist.12-8-913